This company listing is no longer active
Biodexa Pharmaceuticals Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Información clave
4.3%
Tasa de crecimiento de los beneficios
61.2%
Tasa de crecimiento del BPA
| Crecimiento de la industria Biotechs | 11.5% |
| Tasa de crecimiento de los ingresos | -14.0% |
| Rentabilidad financiera | -71.6% |
| Margen neto | -832.1% |
| Última actualización de beneficios | 30 Jun 2022 |
Actualizaciones de resultados anteriores recientes
Desglose de ingresos y gastosBeta
Cómo gana y gasta dinero Biodexa Pharmaceuticals. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Jun 22 | 1 | -5 | 3 | 0 |
| 31 Mar 22 | 1 | -5 | 3 | 0 |
| 31 Dec 21 | 1 | -5 | 3 | 0 |
| 30 Sep 21 | 1 | -7 | 3 | 2 |
| 30 Jun 21 | 1 | -8 | 3 | 2 |
| 31 Mar 21 | 0 | -15 | 4 | 1 |
| 31 Dec 20 | 0 | -22 | 4 | 0 |
| 30 Jun 20 | 0 | -22 | 5 | 0 |
| 31 Mar 20 | 1 | -16 | 5 | 0 |
| 31 Dec 19 | 1 | -9 | 4 | 0 |
| 30 Jun 19 | 2 | -9 | 4 | 0 |
| 31 Mar 19 | 2 | -10 | 4 | 0 |
| 31 Dec 18 | 2 | -10 | 4 | 0 |
| 30 Jun 18 | 1 | -11 | 4 | 0 |
| 31 Mar 18 | 1 | -11 | 4 | 0 |
| 31 Dec 17 | 1 | -12 | 4 | 0 |
| 30 Sep 17 | -3 | -1 | -7 | -5 |
| 30 Jun 17 | 4 | -18 | 10 | 6 |
| 31 Mar 17 | 6 | -19 | 14 | 7 |
| 31 Dec 16 | 1 | -6 | 3 | 0 |
| 30 Sep 16 | 5 | -17 | 12 | 10 |
| 30 Jun 16 | 4 | -13 | 13 | 6 |
Ingresos de calidad: BDRX is currently unprofitable.
Margen de beneficios creciente: BDRX is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: BDRX is unprofitable, but has reduced losses over the past 5 years at a rate of 4.3% per year.
Acelerando crecimiento: Unable to compare BDRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: BDRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7%).
Rentabilidad financiera
Alta ROE: BDRX has a negative Return on Equity (-71.65%), as it is currently unprofitable.